BC Week In Review | Nov 9, 2015
Company News

Cardioxyl, Bristol-Myers deal

Bristol-Myers Squibb will acquire cardiovascular company Cardioxyl for $300 million in combined upfront and near-term milestone payments and up to $1.8 billion in development, regulatory and sales milestones. Cardioxyl is developing lead candidate CXL-1427 , a...
BC Extra | Nov 3, 2015
Company News

BMS acquires Cardioxyl

Bristol-Myers Squibb Co. (NYSE:BMY) will acquire Cardioxyl Pharmaceuticals Inc. (Chapel Hill, N.C.), which is developing cardiovascular therapies including lead candidate CXL-1427 . The second-generation prodrug of nitroxyl (HNO) is in a Phase II study to treat...
BC Week In Review | Mar 3, 2014
Clinical News

CXL-1427: Phase I started

Cardioxyl began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate ascending doses of 24- and 48-hour infusions of IV CXL-1427, starting at a 0.1 µg/kg/min dose, in up to 110 healthy volunteers. Cardioxyl Pharmaceuticals...
Items per page:
1 - 3 of 3